Free Trial

Capricor Therapeutics (CAPR) Stock Price, News & Analysis

-0.01 (-0.16%)
(As of 05/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
289,003 shs
Average Volume
306,549 shs
Market Capitalization
$200.08 million
P/E Ratio
Dividend Yield
Price Target

Capricor Therapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
245.8% Upside
$21.75 Price Target
Short Interest
13.01% of Shares Sold Short
Dividend Strength
News Sentiment
-0.16mentions of Capricor Therapeutics in the last 14 days
Based on 22 Articles This Week
Insider Trading
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.65 out of 5 stars

Medical Sector

852nd out of 921 stocks

Pharmaceutical Preparations Industry

384th out of 416 stocks

CAPR stock logo

About Capricor Therapeutics Stock (NASDAQ:CAPR)

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

CAPR Stock Price History

CAPR Stock News Headlines

Capricor Therapeutics (NASDAQ:CAPR) Now Covered by Oppenheimer
Expert Ratings For Capricor Therapeutics
Here's what to expect from Capricor Therapeutics's earnings report
See More Headlines
Receive CAPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$25.18 million
Book Value
$0.73 per share


Free Float
Market Cap
$196.59 million
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Frank I. Litvack M.D. (Age 59)
    Independent Executive Chairman of the Board
  • Linda Marban Ph.D. (Age 51)
    President, Chief Executive Officer, Director
  • Anthony Bergmann (Age 32)
    Chief Financial Officer, Principal Accounting Officer
  • Karen G. Krasney J.D. (Age 62)
    Executive Vice President, General Counsel
  • Thomas Lyle Copmann Ph.D. (Age 61)
    Vice President - Regulatory Affairs and Drug Development
  • Houman Hemmati M.D.
    Ph.D., Vice President - Medical & Clinical Development, New Therapies
  • Luis Rodriguez-Borlado Ph.D.
    Vice President - Regenerative Therapies
  • Rachel Smith Ph.D. (Age 36)
    Vice President - Research & Development
  • Deborah Ascheim M.D.
    Chief Medical Officer
  • Joshua A. Kazam (Age 40)

CAPR Stock Analysis - Frequently Asked Questions

Should I buy or sell Capricor Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CAPR shares.
View CAPR analyst ratings
or view top-rated stocks.

What is Capricor Therapeutics' stock price target for 2024?

4 brokerages have issued twelve-month price targets for Capricor Therapeutics' shares. Their CAPR share price targets range from $8.00 to $40.00. On average, they expect the company's share price to reach $21.75 in the next twelve months. This suggests a possible upside of 245.8% from the stock's current price.
View analysts price targets for CAPR
or view top-rated stocks among Wall Street analysts.

How have CAPR shares performed in 2024?

Capricor Therapeutics' stock was trading at $4.89 at the beginning of 2024. Since then, CAPR stock has increased by 28.6% and is now trading at $6.29.
View the best growth stocks for 2024 here

When is Capricor Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our CAPR earnings forecast

How were Capricor Therapeutics' earnings last quarter?

Capricor Therapeutics Inc (NASDAQ:CAPR) posted its earnings results on Thursday, February, 29th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.21. The biotechnology company earned $12.09 million during the quarter, compared to the consensus estimate of $5.80 million. Capricor Therapeutics had a negative trailing twelve-month return on equity of 231.68% and a negative net margin of 89.72%.

What ETF holds Capricor Therapeutics' stock?

iShares Neuroscience and Healthcare ETF holds 2,030 shares of CAPR stock, representing 0.30% of its portfolio.

What other stocks do shareholders of Capricor Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Capricor Therapeutics investors own include Marinus Pharmaceuticals (MRNS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Trevena (TRVN), Dynavax Technologies (DVAX), Chesapeake Energy (CHKAQ), OPKO Health (OPK) and Advanced Micro Devices (AMD).

Who are Capricor Therapeutics' major shareholders?

Capricor Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.34%), BNP Paribas Financial Markets (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David B Musket, Paul Gisbert Auwaerter and Xavier Avat.
View institutional ownership trends

How do I buy shares of Capricor Therapeutics?

Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CAPR) was last updated on 5/21/2024 by Staff

From Our Partners